AI-based medical imaging analysis company AIDOT (CEO Jeong Jae-hoon) announced on January 2 that its urinary stone diagnostic AI solution, URO dot AI, has been fully commercialized and is now being utilized in clinical practice at Menpower Urology Hospital.
This deployment is significant as it represents a case where an AI medical device has moved beyond research and demonstration phases to be seamlessly integrated into the workflow of outpatient and diagnostic environments.
URO dot AI is an AI solution that automatically analyzes CT images to quantify urinary stones’ location, size, and number, providing structured diagnostic reports.
At Menpower Urology Hospital, the solution has helped reduce the reading burden on medical staff, shorten patient waiting times, and enable clearer explanations to patients, resulting in tangible improvements in clinical efficiency.
The key aspect of this commercialization lies not only in the AI performance itself but also in its “field adaptability”, allowing integration into existing hospital workflows without disruption.
URO dot AI is designed to be used immediately without additional training for medical staff or changes to clinical processes, addressing one of the main barriers to AI medical device commercialization: practical deployability in real-world clinical settings.
Building on this CT-based commercialization experience, AIDOT plans to sequentially introduce next-generation multimodal AI solutions for the urinary system that combine X-ray and ultrasound imaging.
This technology has already completed patent applications, and prior research has confirmed meaningful performance improvements compared with conventional single-modality imaging diagnostics.
In particular, ultrasound-based AI diagnostics for the urinary system are expected to have high utility in primary care and outpatient settings due to no radiation exposure and enhanced accessibility.
AIDOT aims for wide clinical adoption across healthcare settings, from tertiary hospitals to primary care clinics, through a multimodal AI strategy that leverages X-ray and ultrasound imaging based on clinical needs.
CEO Jeong Jae-hoon stated, "The commercialization of URO dot AI demonstrates that AI diagnostics are no longer just future technology, but a basic infrastructure actively functioning in current clinical practice. We will continue to refine the technology to benefit clinicians and patients and introduce diverse AI solutions based on medical imaging."
The adoption at Menpower Urology Hospital serves as a representative reference case for potential expansion to other urology clinics, screening centers, and primary care facilities, both domestically and internationally.
Hankyung TV / January 2, 2026 / Reporter Yang Jae-jun
